Skip to main content
PLOS One logoLink to PLOS One
. 2022 Nov 3;17(11):e0276193. doi: 10.1371/journal.pone.0276193

A mixed-methods study of factors influencing postpartum intrauterine device uptake after family planning counseling among women in Kigali, Rwanda

Mariama S Tounkara 1, Rosine Ingabire 2, Dawn L Comeau 1, Etienne Karita 2, Susan Allen 3, Julien Nyombayire 2, Rachel Parker 3, Lisa B Haddad 4, Vanessa Da Costa 5, Amanda Tichacek 3, Amelia Mazzei 2, Jeannine Mukamuyango 2, Kristin M Wall 5,*
Editor: Kehinde Sharafadeen Okunade6
PMCID: PMC9632907  PMID: 36327214

Abstract

Introduction

Rwanda has high unmet need for family planning (FP), especially in the postpartum period when women are advised to space pregnancies at least two years for improved maternal-child health. Despite interest in the copper intrauterine device (IUD), a highly cost-effective method, access and uptake remain low. This study aimed to determine factors associated with postpartum IUD (PPIUD) uptake after postpartum family planning (PPFP) counseling as well as provider perceptions of facilitators and barriers to clients’ PPIUD uptake.

Methods

Postpartum women who received PPFP counseling and were less than 6 weeks postpartum were recruited for a case-control study in Kigali, Rwanda in 2018. We recruited n = 74 women who had accepted and n = 91 women who had declined the PPIUD. Multivariate logistic regression analyses evaluated associations between women’s socio-demographics, FP knowledge and decision-making, and the outcome of PPIUD uptake. Six focus groups (FGs) were conducted with FP providers (n = 24) and community health workers (n = 17) trained to deliver PPFP counseling to assess perceptions of PPFP counseling and facilitators and barriers to PPIUD uptake. FG discussions were recorded, translated, and analyzed for themes.

Results

Factors associated (P<0.1) with PPIUD uptake included citing its non-hormonal nature, effectiveness, and duration of protection against pregnancy as advantages. Exclusive male partner control over FP decisions (relative to women’s control or joint decision-making) was associated with non-use. Overall, limited knowledge about some aspects of the PPIUD persisted among clients even after counseling. Provider FGs highlighted client concerns, inconsistent FP messaging, and lack of male partner involvement as factors influencing non-use.

Conclusions

Knowledge of the IUD and its benefits was associated with PPIUD uptake. There is need to refine PPFP counseling messages to address remaining knowledge gaps and concerns. Additionally, male partner involvement in FP counseling and decisions with their partners could be a key strategy to increase both PPIUD and FP uptake in Rwanda.

Introduction

Although increased family planning access has reduced global fertility rates, unintended pregnancies, and unsafe abortions, these outcomes are still relatively frequent in sub-Saharan African countries where unmet need for family planning is common [1]. Unmet need for postpartum family planning (PPFP) is particularly high throughout sub-Saharan Africa [2].

The World Health Organization (WHO) recommends a birth spacing interval of two years for improved maternal-child health [3]. In Rwanda, 52% of pregnancies occur less than two years after the preceding birth [4], 47% of all pregnancies are unintended [5], and 51% of postpartum women have an unmet need for family planning [4]. To ameliorate these issues, Rwanda is spearheading PPFP programs with a particular focus on the long-acting reversible contraception (LARC) methods [6, 7]. LARCs (non-hormonal copper IUDs and hormonal implants) are highly effective, convenient, safe, easy to use, and require infrequent follow-up visits relative to the shorter acting methods [810]. Despite IUDs being less expensive and more cost-effective than other contraceptives, knowledge [11] and uptake are still extremely low and this warrants further exploration [12].

Community health workers (CHWs) and providers can offer counseling to educate women about PPFP, including LARCs 1) during routine antenatal care (ANC) visits, 2) during or after labor and delivery (L&D), 3) pre-discharge/post-partum and 4) at infant vaccination visits [13]. LARCs can be provided while women are at the health facility during delivery or at infant vaccination visits. Convenient times to insert the copper IUD while women are at the health facility include post-placental (within 10 minutes of placental delivery), postpartum (within 48 hours of delivery), at 4–6 weeks postpartum, and during infant vaccination visits [1416]. However, of the 30% of women using modern contraceptive methods in Rwanda, only 3% use the copper IUD while 17% use the implant [7], which is more well-known relative to the IUD. Among post-partum Rwandan women who are using a family planning method, only 2% use an IUD [4].

Projet San Francisco (PSF) developed a multi-level intervention to improve PPFP services in Rwanda with a focus on PPLARC which was implemented in August of 2017 [13]. Based on input from stakeholders, providers, CHWs, and couples/clients, a promotional and educational flipchart was developed to educate women about the PPIUD (along with the full menu of PPFP contraceptive options) to be delivered to women or couples during routine ANC, labor, within 48 hours postpartum, infant vaccination services and in the community by CHWs [13]. Providers from 6 government facilities including hospitals and clinics went through a 2-day didactic session followed by practical training including PPIUD insertion and removal, mock counseling sessions, and post-training tests. CHWs who worked with pregnant women and newborns received 1-day training to review the flipchart. After the first year of implementation, there was a PPIUD acceptance rate of 29% among 9073 women who received one-on-one PPFP counseling [13].

The objectives of the present study were to evaluate factors associated with PPIUD uptake after receipt of PPFP counseling and to assess the barriers and facilitators to PPIUD promotion and uptake as perceived by the PPFP providers and CHWs.

Methods

In this mixed-methods study, quantitative data from a case-control study and qualitative data from focus group discussions (FGDs) were collected and analyzed.

Sample and setting

Convenience samples of participants for the case-control study (with a target recruitment ratio of 1:1) and FGDs were recruited at three government health facilities in Kigali, Rwanda in 2018. Sites were selected because they are high-volume facilities where our PPFP counseling and provision [13] had been implemented almost a year prior [17]. PPFP counseling included information on health benefits of spacing pregnancies, facts (including benefits and side-effects) about all PPFP methods including the IUD, and description of the PPLARC insertion procedures.

Eligible participants for the case-control study must: 1) have received PPFP promotions and delivered at any of the PSF-affiliated facilities; 2) speak Kinyarwanda (the local language); and 3) have voluntarily agreed to participate and provided written informed consent. Verification of the women having previously received our counseling intervention was ascertained by checking FP promotion and insertion government logbooks at each facility.

Eligible participants for the FGDs were PPFP trained and certified providers (physicians, nurses, midwives) and CHWs who had been promoting PPFP use for at least 4 months prior to FGDs.

Recruitment

For the case-control study PPIUD users were recruited face-to-face during PPIUD follow-up visits and 6-week infant vaccination services at the clinic. Nonusers (women who used a non-LARC method or no method at all) were selected from postpartum and infant vaccinations visits. Providers for the FGDs were recruited during work breaks and after work. CHWs were recruited during their monthly check-in meetings with nurse counselors.

Data collection

Quantitative strand

Two separate semi-structured surveys (one for PPIUD users and another for nonusers) included closed-ended questions to assess sociodemographic characteristics, contraceptive use history, reproductive history and sources of contraceptive information. Two questions assessed knowledge of timing related to PPIUD insertion after counseling–one asked for a non-prompted, spontaneous response from participants while the other provided women with a list of possible responses that they could choose from. Open-ended questions assessed knowledge about postpartum family planning, PPIUD use, benefits, and facts as well as family planning decision-making factors. PPIUD users were also asked about expulsions and side-effects. On a five-point Likert-scale, PPIUD users were asked about the service delivery environment and overall satisfaction with the intervention and the method. PPIUD nonusers were asked about future contraceptive plans.

The surveys were revised with the help of PSF staff and translated from English into Kinyarwanda by native speakers to ensure content and semantic equivalence. They were pilot tested among six PPIUD users and eight nonusers and then iteratively revised to improve question phrasing, order, and for overall linguistic comprehension and cultural propriety. The surveys were administered during regular government health facility hours by four trained PSF counselors using tablets through the digital survey platform, Survey CTO (Dobility, Cambridge, USA). Surveys took 10–15 minutes to deliver.

Qualitative strand

The FGD guides were developed from the PPFP counseling tools and observations made during promotions and based in grounded theory. The questions explored the providers’ perceptions of the facilitators and barriers to the intervention and client PPIUD uptake. All six FGDs (two consisting of 17 CHWs and four of 24 providers) were led by trained PSF staff and nurse counselors. FGDs were conducted from July to August 2018 and ranged from 30 minutes to 2 hours in duration. FGDs were audiotaped and detailed notes were taken to identify themes.

Quantitative data analysis

Data was checked for completeness, cleaned, and coded for analysis. Quantitative analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA). Age was estimated by subtracting the year of birth from the year of data collection (2018).

Qualitative responses to the open-ended questions were quantized [18]. This conversion of qualitative into quantitative data allowed for statistical assimilation with the other obtained quantitative data. Data regarding participant and partner control in FP decision making was collected with three response categories: woman alone, man alone, or joint control. The point estimates for woman alone and joint control were both significant and of similar magnitude and direction relative to the null; thus, we decided to collapse those two categories.

Numerical and categorical responses were reported as means and standard deviations and frequencies and percentages, respectively. These data were stratified by the outcome of interest which was current PPIUD use versus nonuse. This was followed by bivariate analyses to test associations between sociodemographic, reproductive characteristics, PPIUD knowledge, decision-making factors, and the outcome of PPIUD uptake. Chi-square tests (or Fisher’s exact tests) and independent t-tests were used to assess for whether covariate distributions were statistically significantly different by the outcome. Variables that significantly differed by outcome status (P<0.1) in bivariate analyses were evaluated in crude logistic regression models and prevalence odds ratios (ORs), 95% confidence intervals (CIs), and p-values were obtained. The variables were checked for evidence of multicollinearity based on a Spearman correlation coefficient of >0.8 to ensure that the predictors were not highly associated with each other. Selection for the adjusted multivariate logistic regression model was considered at P<0.1 due to the formative nature and relatively limited sample size of this study. Backwards selection methods in SAS were used to obtain the final logistic regression model [19]. Variables attaining significance at P<0.1 in the multivariate analysis were retained for the final adjusted logistic model.

Qualitative data analysis

Thematic analysis was used to identify the perceptions of PPIUD uptake in the FGDs by two analysts. Themes derived from the data related to facilitators and barriers to uptake that contextualized the quantitative survey findings, or provided new insight, were identified until saturation was achieved and included in the analysis. Participants did not provide feedback on the FGD findings.

Ethical considerations

Ethical clearance was obtained from the Emory University Institutional Review Board and the Rwanda National Ethics Committee. Written informed consent was obtained from all study participants and all participants were informed about the nature and goals of the research. Each individual was compensated with 3,000 Rwandan Francs, an amount agreed upon by the local IRB.

Results

Quantitative strand

Demographic and reproductive characteristics

The case-control study included 165 postpartum women. PPIUD users (n = 74) were surveyed during PPIUD follow-up visits (n = 54) and infant vaccination (n = 20) services. PPIUD nonusers (n = 91) were surveyed during postpartum (n = 26) and infant vaccination services (n = 65) (S1 Fig).

There were no significant differences between groups in age, marital status, cohabitation, having health insurance, religion, education level, income, parity, or future desire for more children (Table 1). Over one in five (22%) women indicated that their most recent contraceptive method prior to pregnancy was a LARC, while 45% had not been using contraception. Receiving promotions at L&D (81% vs 46%, P < .001) was significantly associated with PPIUD uptake with non-PPIUD users more likely to report promotions at ANC (61% PPIUD vs 78% non-PPIUD, P = .016), infant vaccination (22% vs 47%, P = .001), and postpartum (19% vs 33%, P = .042) were. Across both groups, 62% of respondents had planned their recent pregnancy and 90% planned to breastfeed exclusively. Exclusive male partner control over FP decision making was associated with non-PPIUD use (relative to woman only control or joint decision making (P = .015). More users than nonusers reported that their fertility plans impacted their family planning decisions (72% vs 9%, P < .001). About 29% of nonusers who were not using contraception at the time of the survey planned to use an IUD within 3 months of the survey.

Table 1. Sociodemographic, fertility and reproductive characteristics of respondents by PPIUD use (N = 165).
Variables Total (N = 165) PPIUD Users (n = 74) PPIUD Nonusers (n = 91) P value
Age, mean (SD), y 28.9 (5.7) 28.3 (6.3) 29.4 (5.2) .24
Relationship Status, n (%)
Married 127 (77.0) 54 (73.0) 73 (80.2) .27
Unmarried (Single, Divorced/Separated, Widow, Other) 38 (23.0) 20 (27.0) 18 (19.8)
Living Situation, n (%)
Cohabiting with partner 144 (87.3) 63 (85.1) 81 (89.0) .46
Other (alone, with parents/family, roommates) 21 (12.7) 11 (14.9) 10 (11.0)
Religion, n (%)
Catholic 48 (29.1) 26 (35.1) 22 (24.2) .28
Pentecostal 78 (47.3) 31 (41.9) 47 (51.6)
Other (Seventh Day Adventists, Jehovah’s Witnesses, Anglican, Baptist, Muslim, Other, None) 39 (23.6) 17 (23.0) 22 (24.2)
Education Level, n (%)
No schooling 26 (15.8) 11 (14.9) 15 (16.5) .96
Primary 79 (47.9) 36 (48.6) 43 (47.3)
Other (Secondary, College/University) 60 (36.4) 27 (36.5) 33 (36.3)
Work or exchange services for money, n (%)
Yes 75 (45.5) 36 (48.7) 39 (42.9) .46
No 90 (54.6) 38 (51.4) 52 (57.1)
Mutuelle (Government Health Insurance), n (%)
Yes 155 (93.9) 67 (90.5) 88 (96.7) .11
Noa 10 (6.1) 7 (9.5) 3 (3.3)
Parity, n (%)
0–1 47 (28.5) 23 (31.1) 24 (26.4) .77
2–3 77 (46.5) 34 (45.9) 43 (47.3)
4 or more 41 (24.8) 17 (23.0) 22 (26.4)
No. of living children, mean n (%)
0–1 50 (30.3) 23 (31.1) 27 (29.7) .98
2–3 83 (50.3) 37 (50.0) 46 (50.5)
4 or more 32 (19.4) 14 (18.9) 18 (19.8)
Most recent contraception method prior to pregnancy, n (%)
LARC (Copper T-IUD, Implant) 36 (21.8) 20 (27.0) 17 (18.7) .32
Other (Condoms, Pills, Injectables) 55 (33.3) 25 (33.8) 29 (31.9)
Never used contraception 74 (44.8) 29 (39.2) 45 (49.5)
PPIUD Promotion Service Venuesb, n (%)
Antenatal Care 116 (70.3) 45 (60.8) 71 (78.0) .016
Infant Vaccination 59 (35.8) 16 (21.6) 43 (47.3) .001
Labor & Delivery 102 (61.8) 60 (81.1) 42 (46.2) < .001
Postpartum (before discharge) 44 (26.7) 14 (18.9) 30 (33.0) .042
Community Health Worker 7 (4.2) 2 (2.7) 5 (5.5) .46
Was the most recent pregnancy planned? n (%)
Yes 102 (61.8) 45 (60.8) 57 (62.6) .81
No 63 (38.2) 29 (39.2) 34 (37.4)
Breastfeeding Plans, n (%)
Yes, exclusively 149 (90.3) 69 (93.2) 80 (87.9) .25
Yes, non-exclusively 16 (9.7) 5 (6.8) 11 (12.1)
Final Decision Maker regarding contraception, n (%)
Me & My Partner and I 139 (84.2) 68 (91.9) 71 (78.0) .015
My Partner 26 (15.8) 6 (8.1) 20 (22.0)
Desire More Children, n (%)
Yes 91 (55.2) 36 (48.6) 55 (60.4) .13
No/undecided 74 (44.9) 38 (51.4) 36 (39.6)
Did your fertility Plans Impact FP Decision?, n (%) < .001
Yes 61 (37.0) 53 (71.6) 8 (8.8)
No 104 (63.0) 21 (28.4) 83 (91.2)

Abbreviations: CHW, community health worker; FP, family planning; IUD, intrauterine device; PPIUD, postpartum intrauterine device; PPLARC, postpartum long-acting reversible contraception; SD, standard deviation, USD, United States Dollar.

P value derived from two-tailed independent sample t-test for continuous variables and chi-square test for categorical variables (or Fisher’s exact test for categorical variables with 20% of expected cell counts less than 5).

a Includes insurance that is not mutuelle.

b Select all that apply.

Family planning and PPIUD knowledge

There were notable family planning and contraceptives knowledge gaps among all respondents (Table 2). When asked about the recommended time for pregnancy after birth, 48% of the women correctly reported at least 2 years. When prompted to support their answer, 55% of respondents explained that birth spacing is important to ensure child health, to allow the mother’s body to recuperate from the stress of pregnancy, and to have sufficient time for breastfeeding. When asked an open-ended question about what they had learned about the PPIUD, women reported that it was nonhormonal (87%), long-term (55%), highly effective (31%), reversible (17%), easy to remove whenever needed (9%), easily inserted after delivery (9%), and that you only had to pay once for the IUD compared to paying per provision when using injectables or pills (6%). While overall knowledge was low, users, compared to non-users, were more likely to spontaneously volunteer, without being prompted, that the IUD can be easily inserted immediately after delivery (14% vs 4%, P = .037), required no further action once inserted (14% vs 4%, P = .037), easy to remove when needed (16% vs 3%, P = .004), paying once for IUD compared to paying per provision when using injectables or pills (12% vs. 1%, P = .003).

Table 2. Knowledge about family planning and the PPIUD among respondents by PPIUD use.
Variables Total (N = 165) PPIUD Users (n = 74) PPIUD Nonusers (n = 91) P value
Recommended Pregnancy spacing after last birth, n (%)
No limit 5 (3.0) 4 (5.4) 1 (1.1) .18
2 years 80 (48.5) 33 (44.6) 47 (51.6)
I Don’t Know or Don’t remember 52 (31.5) 21 (28.4) 31 (34.1)
Other ab 28 (17.0) 16 (21.6) 12 (13.2)
Reason for recommended pregnancy spacing after last birth (open-ended question)a (n = 112), n (%)
To ensure healthy growth of child 62 (55.4) 21 (40.4) 41 (68.3) .003
Otherd
PPIUD Knowledge after PPIUD counselingc, g, n (%)
Highly effective 51 (30.9) 28 (37.8) 23 (25.3) .082
Long-term 90 (54.5) 38 (51.4) 52 (57.1) .46
Reversible 28 (17.0) 16 (21.6) 12 (13.2) .15
Can be easily inserted immediately after delivery 14 (8.5) 10 (13.5) 4 (4.4) .037
Doesn’t use hormones 143 (86.7) 66 (89.2) 77 (84.6) .39
Once inserted no other action required from client to prevent pregnancy 14 (8.5) 10 (13.5) 4 (4.4) .037
Easy to remove whenever needed 15 (9.1) 12 (16.2) 3 (3.3) .004
If you use injectable or pills, you need to pay per provision while IUD you pay only once 10 (6.1) 9 (12.2) 1 (1.1) .003
Othere 29 (17.6) 12 (16.2) 17 (18.7) .68
Possible PPIUD Side Effectsc, n (%)
Cramping and backache for few days after insertion 64 (38.8) 32 (43.2) 32 (35.2) .29
Spotting between periods or heavy periods 29 (17.6) 12 (16.2) 17 (18.7) .68
Heavy periods after menses 41 (24.8) 17 (23.0) 24 (26.4) .62
Other 49 (29.7) 23 (31.1) 26 (28.6) .73
Recommended PPIUD Insertion Timec, h, n (%)
Post placental (<10mins) 143 (86.7) 67 (90.5) 76 (83.5) .19
10 mins– 48 hours Postpartum 50 (30.3) 23 (31.1) 27 (29.7) .84
4–6 weeks 108 (65.5) 41 (55.4) 67 (73.6) .014
Otherf 28 (17.0) 12 (16.2) 16 (17.6) .82
Recommended PPIUD Insertion Time, n (%)
Correct: citation of all three: Post placental (<10mins), 10mins– 48 hours postpartum, 4–6 weeks 33 (20.0) 15 (20.3) 18 (19.8) .94
Incorrect: all other responses 132 (80.0) 59 (79.7) 73 (80.2)
Expulsion Possible, n (%)
Yes 101 (61.2) 49 (66.2) 52 (57.1) .23
No 64 (38.8) 25 (33.8) 39 (42.9)
How PPIUD prevents pregnancy (n = 163), n (%) .91
It stops the meeting of the spermatozoa and ovum 99 (60.7) 44 (60.3) 55 (61.1)
I Don’t Know/Don’t Remember/Other 64 (39.3) 29 (39.7) 35 (38.9)
Heard about PPIUD prior to counseling, n (%)
Yes 41 (25) 17 (23.0) 24 (26.0) .62
No 124 (75) 57 (77.0) 67 (67.0)

a Coded qualitative response.

b “Other” option includes 3, 4, 5, and 10 years.

c Select all that apply.

N’s may not add to totals due to missingness of data for questions that participants were not required to answer.

d Other reasons for recommended pregnancy time after birth include: mother’s body can prepare for next baby, improve overall health of family (economically and physically), birth spacing, enough time for breastfeeding.

eOther PPIUD knowledge include: IUD doesn’t have many side effects, no frequent follow-up visits, may be removed at any time.

f Other responses for side effects include: None, I Don’t Know/I don’t remember.

g Non-prompted, spontaneous responses from women

h Respondents were read the various response options

When asked open-ended questions about the possible side-effects associated with PPIUD use, 39% reported cramping and backache, heavy periods after menses (25%), spotting between periods or heavy periods (18%), and other (30%). Among the women who chose “Other” for side-effects, an open response option was provided; 55% reported that the PPIUD had no side-effects and 25% did not know or remember. When asked to select from various response options which were provided about what time frame PPIUD can be inserted, respondents identified post-placental (87%), 10 mins–48 hours postpartum (30%), and 4–6 weeks (66%), however only 30 (20%) of the women correctly reported that PPIUDs can be inserted at all 3 times. Women who reported that the PPIUD can be inserted only between 4–6 weeks were less likely to be users (55% vs. 74%, P = .014). Only 61% indicated that expulsion was possible. When asked to explain how the method prevents pregnancy, 61% reported that it stops the spermatozoa and ovum from meeting. Regarding women’s general awareness about the PPIUD, 25% had heard about the method previously from informal social networks such as peers, neighbors, and other users.

Reasons for acceptance or rejection of the PPIUD

Women were also asked about factors that impacted their decisions to either accept or reject the PPIUD. Among users, the top factors indicated were that the method is nonhormonal (74%), long-term (58%), and highly effective (38%) (Table 3). Almost all users (99%) reported that they found the promotions useful in their decisions, and 88% stated that they would not have gotten the method without them. Partner’s rejection of PPIUD (28%), absence of partner during decision time (19%), religion (14%), and influence from other women (13%) were cited as reasons for PPIUD non-uptake. Other reasons reported by nonusers were delivering at a different facility, myths about the IUD being cancer-causing, genital infections, discomfort during sexual intercourse and pregnancy while on method were cited as reasons for PPIUD non-uptake.

Table 3. Reasons for acceptance and rejection of PPIUD.
Reasons for PPIUD Acceptance a n (%)
Doesn’t use hormones 55 (74.3)
Long-term 43 (58.1)
Highly effective 27 (36.5)
Other b 13 (17.6)
Reversible 11 (14.9)
Once inserted no other action required from client to prevent pregnancy 11 (14.9)
Can be easily inserted immediately after delivery 9 (12.2)
Easy to remove whenever needed 9 (12.2)
If you use injectable or pills, you need to pay per provision while IUD you pay only once 9 (12.2)
Used to be happy on it/Happy testimony 9 (12.2)
PPIUD promotions useful in decision making?
Yes 73 (98.6)
No 1 (1.4)
Would you have gotten the PPIUD anyway without promotions?
No 65 (87.8)
Yes 9 (12.2)
Reasons for PPIUD Rejection a
Otherc 29 (31.9)
My partner refused to use PPIUD or doesn’t like it 25 (27.5)
My partner was not present 17 (18.7)
Religious reasons 13 (14.3)
Influence from women in the same room 12 (13.2)
Unhappy peer testimony 4 (4.4)
Side-effects 1 (1.1)
Why did you choose your current method?
Preference for current method and its benefits 51 (56.0)
None/no reason 18 (19.8)
Partner’s choice 6 (6.6)
Insufficient decision-making time 5 (5.5)

a Select all that apply so percentages are more than 100%.

b “Other” responses include: Little/no side effects compared to other methods, secrecy of where IUD is placed.

c “Other” responses include: delivering at different facility, rumors and myths (cancer, tumor, genital infections, discomfort during sexual intercourse, pregnancy while on IUD).

Multivariate regression

Variables significant at P<0.01 were included in the final multivariate logistic model. Women who reported that PPIUD can be inserted 4–6 weeks after delivery were less likely to uptake the method than those who did not (adjusted odds ratio [aOR], 0.17; 95% CI, 0.06–0.44; P < .001) (Table 4). Compared to women whose partner alone made the final PPFP decision, women who made independent and joint decisions with their partners were more likely to uptake the PPIUD (aOR, 4.04; 95% CI, 1.12–14.6; P = .033). Finally, the odds of accepting the PPIUD were higher among women who reported taking their fertility intentions into account when making their PPFP decisions versus those who did not (aOR, 48.5; 95% CI, 16.4–143.4; P < .001).

Table 4. Multivariate analysis of factors associated with PPIUD use.
Variables Bivariate analysis Logistic regression analysis
cOR (95% CI) P value Full model aOR (95% CI) P value Reduced model aOR (95% CI) P value
Recommended Pregnancy Time after birth Not included
Other 1 [Reference] 1 [Reference]
No limit 3.00 (0.30–30.4) .17 4.09 (0.19–87.7) .30
At least 2 years 0.53 (0.22–1.26) .092 0.73 (0.20–2.64) .24
I Don’t Know or Don’t remember 0.51 (0.20–1.29) .091 0.91 (0.23–3.55) .51
PPIUD Knowledge (yes versus no) Not included
Highly effective 1.80 (0.92–3.51) .084 2.01 (0.66–6.1) .22
Can be easily inserted immediately after delivery 3.40 (1.02–11.3) .046 1.39 (0.21–9.09) .73
Once inserted no other action required from client to prevent pregnancy 3.40 (1.02–11.3) .046 2.20 (0.35–13.9) .40
Easy to remove whenever needed 5.68 (1.54–21.0) .009 2.22 (0.33–14.8) .41
If you use injectable or pills, you need to pay per provision while IUD you pay only once 12.5 (1.54–100.8) .018 0.93 (0.05–16.8) .96
Knowledge of PPIUD insertion time option (yes versus no)
4–6 weeks 0.45 (0.23–0.86) .015 0.13 (0.05–0.39) < .001 0.17 (0.06–0.44) < .001
Final Decision Maker regarding PP FP
My partner 1 [Reference] .019 1 [Reference] .095 1 [Reference] .033
Me & My Partner and I 3.19 (1.21–8.43) 3.21 (0.82–12.6) 4.04 (1.12–14.6)
Fertility Plans Impact FP Decision
No 1 [Reference] < .001 1 [Reference] < .001 1 [Reference] < .001
Yes 26.2 (10.8–63.4) 44.4 (14.2–138.9) 48.5 (16.4–143.4)

Abbreviations: aOR, adjusted odds ratio; CI, confidence interval; cOR, crude odds ratio; FP, family planning; IUD: intrauterine device; OR, odds ratio; PP, post-partum; PPIUD, postpartum intrauterine device.

P value <0.1

Qualitative strand

Forty-one promoters participated in focus groups (17 CHWs and 24 nurses, midwives and physicians). The data highlighted the following themes that complemented survey findings: low PPIUD knowledge, the importance of male partner involvement in IUD decision-making, rumors and myths, concerns and side effects, inconsistent messages from providers, and perception of intervention as factors that impacted acceptance or rejection of PPIUD.

Low PPIUD knowledge

Providers reported that clients had low IUD-specific knowledge, including benefits of postpartum insertion, the insertion and removal process, how it prevents pregnancy, and why it is highly efficacious relative to other contraceptives. Providers shared that clients are generally suspicious about the IUD as it is new to many Rwandan women, and its placement through the cervix makes them uncomfortable. It is easier for women to trust contraceptive methods like pills and implants because they are visible and palpable unlike an IUD.

Providers explained that for some women, especially young first-time mothers, unfamiliarity with the female anatomy and medical terms like “placenta” and “cervix” cause confusion. Some women mistake the cervix for the vagina and do not understand how a metal placed in the vagina will not expulse or cause harm. To address this fear, a hospital provider stated [we use] didactic materials, an actual IUD and the pictures within the flip chart [to] facilitate the promotion to show them what we are explaining. They also explain that the post-placental insertion time is ideal because the cervix is large and open, making the device easier to place, without causing pain or discomfort. Providers reported that they emphasize the nonhormonal, long-acting and effective nature of the PPIUD.

Male partner involvement in IUD decision-making

Providers discussed the important role men can play in a woman’s decision to use an IUD.

Some women hear about the PPIUD during ANC visits and inform their partners about it, who later accompany them to the follow-up visits to learn more about it. According to the providers, couples counseling during ANC is the most effective time to deliver the intervention because the couples have sufficient time to ask questions and receive information that will lead to informed decisions. A nurse stated, “During the couple counseling the promotion is easier compared to when a woman is alone, because men are more convinced on family planning than women. Once they are counseled and understand the benefits like the economic and financial impact, they are more “receptive and supportive.”

Rumors and myths

Providers explained that some women may decide to uptake the PPIUD during ANC visits. However, rumors and myths (i.e., the IUD is harmful, moves to other parts of the body, aborts pregnancies, causes infertility) circulated by peers and neighbors during community gatherings like community workdays may dissuade women from adopting the method. For example, a HC provider stated: “Rumors and myths that women have include: IUDs can disappear, cause discomfort during sexual intercourse, or cause infection and cancer…so for this [reason] it is not easy to convince them [to use an IUD]. These rumors may perpetuate fear and cause distrust between women and their HC providers. To dispel these rumors, providers explained that increasing the use of satisfied IUD user testimonies and allowing medical staff to go into communities for PPFP promotion would be beneficial.

Concerns and side-effects

Providers felt PPIUD fears and concerns are prompted by peers, neighbors and unhappy users. A HC provider described that segments of the flipchart that address side-effects prompted clients to ask the most questions. He stated, “the part of side-effects raises more questions …they [the clients] ask you if IUD [has] side-effects like weight gain, infection, backache… mostly [these questions are asked by] those who have had side-effects on other contraceptive methods. Some clients expressed that they would experience a reduction of vaginal secretions during sexual intercourse because of the IUD. Providers explained that for women who undergo difficult deliveries that lead to tears or episiotomy, fear about additional pain during the IUD insertion is a concern. The reversibility of the PPIUD also raised concerns for some women who plan to have more children. According to a CHW, “some clients think that only the person who inserts the IUD can take it out. To address these concerns, providers explained to the women that any trained staff can remove their IUD at their request. Moreover, providers expressed that some clients were concerned about inconsistent messages (e.g., that pills and injectables are nonhormonal or that the IUD is an abortifacient).

Perception of intervention

Providers spoke to the strength of the PPIUD service delivery and trainings they received which facilitates their ability to counsel clients effectively. They also underscored the importance of the continuity and repetition of messages during units of care like ANC, L&D, infant vaccination and follow-up. Participants also highlighted the fact that the PPIUD flipchart is a helpful resource to refer to and confirm the information they deliver. A provider suggested having an educational video playing in the waiting rooms to aid in PPIUD promotions, especially when providers are busy with other activities. Another recommended “distributing individual brochures may help in the promotion as a woman can continue reading the information once home, and if she hears rumors, she may again refer to the brochure.

Discussion

This study employed a mixed-methods approach which found consistency between qualitative and quantitative data to understand factors associated with PPIUD uptake after PPFP education. Woman alone or joint FP decision making was associated with uptake relative to exclusive male partner control. Additionally, not being able to spontaneously report that the IUD can be inserted immediately post-partum or within 48 hours of delivery was associated with non-uptake of the method. PPIUD users reported that the provision of PPFP counseling at the PSF-affiliated facilities was critical in their decision to uptake an IUD. This demonstrates the strength of the intervention and highlights the need for more PPIUD competent providers.

According to WHO, PPFP counseling should ideally begin during ANC, however initial counseling during early labor and immediate postpartum are also acceptable [20]. In this study, 61% and 81% of women reported being counseled in ANC and L&D, respectively. Providers explained that once promotions have occurred during ANC, subsequent promotions are easier because they are able to address residual questions and concerns and emphasize the method’s advantages. Other literature similarly reports that repeated counseling during the ANC and postpartum periods can positively impact contraceptive use [21].

A WHO report showed that a common reason for nonuse of contraception is lack of awareness [20]. Findings from the study show that the majority (77%) of the study population were not aware of the PPIUD prior to PPFP counseling. Contraceptive provision in many sub-Saharan African countries has focused predominantly on short-terms methods such as condoms, injectables, and pills [2226]. Preference for other contraceptive methods and their benefits was also a common reason for nonuse.

Overall, PPIUD knowledge gaps persisted after PPFP counseling. Only 20% of women could correctly identify all the possible PPIUD insertion times. After receipt of PPFP counseling, <9% of respondents spontaneously (without prompting) reported that the IUD can be easily inserted immediately after delivery, requires fewer visits, and is removable whenever needed. A Tanzanian study on women’s perspectives on, and experiences of using the PPIUD suggested that women’s limited knowledge of PPIUD advantages may have stemmed from incomplete contraceptive counseling [27]. These findings highlight domains for further improvement of PPFP counseling. When faced with a new method that is different in several ways from more familiar methods, it is also challenging to retain multiple pieces of information after only one presentation.

Most women were motivated to use the PPIUD due to its lack of hormone-related side effects, effectiveness, ability to breastfeed, reduced follow-up visits and duration of protection against pregnancy; these findings are consistent with other studies [24, 28]. According to providers, women expressed misconceptions and concerns related to PPIUD use, including the risk of cancer, negative impact on sexual experiences, possible infections, and pain. Fear of side effects, and longstanding myths and misconceptions such as infection and infertility about the IUD have been associated with declining the method in other studies [24, 25, 2931]. Previous studies also show that IUD misinformation has been spread by local informal social networks, unhappy peer IUD users, and through religious authorities [25, 30, 3234]. Providers can be trained to address these concerns during counseling.

Partner involvement was a salient factor in women’s decisions; 46% of PPIUD nonusers indicated that partner’s absence and refusal of the method led to their rejection of the PPIUD. This finding was echoed by providers who expressed that partner presence during counseling impacts women’s FP decisions. Numerous studies have also found partner’s involvement to be very fundamental in FP decisions in many sub-Saharan African countries [24, 25, 29, 31, 34, 35]. For example, in a study of 1,914 pregnant women in Ghana, partner attitudes (specifically positive attitudes towards LARC) were a key component in PPFP decision-making for 80% of couples [35]. It may be highly beneficial to provide the PPIUD educational intervention during the first ANC visit, which >80% of Rwandan male partners attend [36].

Some limitations warrant consideration. Though this is one of few exploratory studies to incorporate both client and provider perspectives related to PPIUD use, the small sample size for the case-control study limits our ability to rule out type II error. The sample is more generalizable to urban women who have access to healthcare. It is possible that the nonusers surveyed prior to 6 weeks had intentions to, or did, take up the PPIUD within the 6-week study time frame. Additionally, the number of women approached to participate who declined was not recorded thus a response rate could not be obtained. Our focus groups size was larger than is customary to ensure proper elicitation of responses from all participants, though our facilitators had many years of experience conducting similar focus groups. Lastly, social desirability bias when collecting self-reported information is possible.

Conclusion

Taking the service delivery perspective into consideration when developing family planning programs may be important as providers can reveal nuanced information that may not be provided by clients. The present study highlighted knowledge of and concerns about the PPIUD as well as how male partner involvement in family planning decisions may influence PPIUD uptake. Widespread campaigns about the IUD’s advantages and safety, and proactive counseling to address couples’ specific fears may increase awareness and uptake of the method. These efforts could aim to improve knowledge and overcome misconceptions related to all available contraceptives with the ultimate goal of improved client-centered counseling and joint decision-making. In the Rwandan context, community promotions can occur during community events led by CHWs. Our findings may inform how to iteratively refine our already successful PPFP intervention which can be scaled-up to meet the contraceptive needs of postpartum women in Rwanda.

Supporting information

S1 Fig. Flowchart for case-control study participant recruitment.

(DOCX)

S1 Questionnaire. Inclusivity in global research questionnaire.

(DOCX)

Data Availability

All relevant data are available on Harvard Dataverse: https://doi.org/10.7910/DVN/GMXIMW.

Funding Statement

This work was supported by the Bill & Melinda Gates Foundation [OPP1160661]. Additional support came from the Emory University Research Council Grant [URCGA16872456], Emory Global Field Experience Award, the Emory Center for AIDS Research [P30 AI050409], the National Institutes of Health [NIAID R01 AI51231; NIAID R01 AI64060; NIAID R37 AI51231], and Emory AITRP Fogarty [5D43TW001042]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Bongaarts J, Casterline J. Fertility Transition: Is sub-Saharan Africa Different? Popul Dev Rev. 2013;38(Suppl 1):153–68. Epub 2013/02/01. doi: 10.1111/j.1728-4457.2013.00557.x . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Guttmacher Institute. Adding It Up: Investing in Contraception and Maternal and Newborn Health, 2017 2017 [cited 2019 March 28]. https://www.guttmacher.org/fact-sheet/adding-it-up-contraception-mnh-2017.
  • 3.World Health Organization. Report of a WHO Technical Consultation on Birth Spacing. Geneva, Switzerland: 2005.
  • 4.USAID, MCHIP. Family Planning Needs during the First Two Years Postpartum in Rwanda. 2010.
  • 5.Basinga P, Moore AM, Singh S, Remerz L, Birungi F, Nyirazinyoye L. Unintended Pregnancy and Induced Abortion in Rwanda: Causes and Consequences. New York: Guttmacher Institute, 2012. [Google Scholar]
  • 6.FHI360. Assessing the Feasibility of Postpartum IUD Provision in Rwanda. 2013.
  • 7.FP2020. Rwanda FP2020 Core Indicator Summary Sheet: 2017–2018 Annual Progress Report Rwanda: 2017.
  • 8.American College of Obstetricians and Gynecologists [ACOG]. Committee Opinion No. 670: Immediate Postpartum Long-Acting Reversible Contraception. Obstetrics and gynecology. 2016;128(2):e32–7. Epub 2016/07/28. doi: 10.1097/AOG.0000000000001587 . [DOI] [PubMed] [Google Scholar]
  • 9.Kaneshiro B, Aeby T. Long-term safety, efficacy, and patient acceptability of the intrauterine Copper T-380A contraceptive device. International Journal of Women’s Health. 2010;2:211–20. doi: 10.2147/ijwh.s6914 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Kulier R, O’Brien PA, Helmerhorst FM, Usher-Patel M, D’Arcangues C. Copper containing, framed intra-uterine devices for contraception. The Cochrane database of systematic reviews. 2007;(4):Cd005347. Epub 2007/10/19. doi: 10.1002/14651858.CD005347.pub3 . [DOI] [PubMed] [Google Scholar]
  • 11.Grabbe K, Stephenson R, Vwalika B, Ahmed Y, Vwalika C, Chomba E, et al. Knowledge, Use, and Concerns about Contraceptive Methods among Sero-Discordant Couples in Rwanda and Zambia. Journal of Women’s Health. 2009:1449–56. Epub September 2009. doi: 10.1089/jwh.2008.1160 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Wall KM, Ingabire R, Allen S, Karita E. Cost per insertion and couple year of protection for postpartum intrauterine devices and implants provided during service scale-up in Kigali, Rwanda. Gates Open Research. 2020. Epub 2018. doi: 10.12688/gatesopenres.12858.4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Ingabire R, Nyombayire J, Hoagland A, Da Costa V, Mazzei A, Haddad L, et al. Evaluation of a multi-level intervention to improve postpartum intrauterine device services in Rwanda [version 2; referees: 1 approved, 2 approved with reservations]. Gates Open Research. 2018;2(38). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Lopez LM, Bernholc A, Hubacher D, Stuart G, Van Vliet HA. Immediate postpartum insertion of intrauterine device for contraception. Cochrane Database of Systematic Reviews. 2015;(6). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.FHI360. Research Findings: Integration of Postpartum Family Planning with Child Immunization Services in Rwanda. 2013.
  • 16.Dulli LS, Eichleay M, Rademacher K, Sortijas S, Nsengiyumva T. Meeting Postpartum Women’s Family Planning Needs Through Integrated Family Planning and Immunization Services: Results of a Cluster-Randomized Controlled Trial in Rwanda. Global health, science and practice. 2016;4(1):73–86. doi: 10.9745/GHSP-D-15-00291 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Espey J, Ingabire R, Nyombayire J, Hoagland A, Da Costa V, Mazzei A, et al. Postpartum long-acting contraception uptake and service delivery outcomes after a multilevel intervention in Kigali, Rwanda. BMJ Sexual & Reproductive Health. 2020. Epub 2020. doi: 10.1136/bmjsrh-2020-200741 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Sandelowski M, Voils CI, Knafl G. On Quantitizing. J Mix Methods Res. 2009;3(3):208–22. Epub 2009/10/30. doi: 10.1177/1558689809334210 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Goodenough AE, Hart AG, Stafford R. Regression with empirical variable selection: description of a new method and application to ecological datasets. PLoS One. 2012;7(3):e34338. Epub 2012/04/06. doi: 10.1371/journal.pone.0034338 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.WHO, USAID, MCHIP. Programming strategies for Postpartum Family Planning. Geneva: 2013.
  • 21.MCHIP, PSI. PPIUD Services: Start-Up to Scale-Up Regional Meeting Burkina Faso: February 3–5, 2014 Meeting Report. Washington, DC: 2014.
  • 22.Wall KM, Haddad L, Vwalika B, Htee Khu N, Brill I, Kilembe W, et al. Unintended pregnancy among HIV positive couples receiving integrated HIV counseling, testing, and family planning services in Zambia. PloS one. 2013;8(9):e75353–e. doi: 10.1371/journal.pone.0075353 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Allen S, Serufilira A, Gruber V, Kegeles S, Van de Perre P, Carael M, et al. Pregnancy and contraception use among urban Rwandan women after HIV testing and counseling. American journal of public health. 1993;83(5):705–10. Epub 1993/05/01. doi: 10.2105/ajph.83.5.705 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Bryant AG, Hamela G, Gotter A, Stuart GS, Kamanga G. Reasons for Intrauterine Device Use, Discontinuation and Non-Use in Malawi: A Qualitative Study of Women and their Partners. Afr J Reprod Health. 2015;19(4):50–7. . [PubMed] [Google Scholar]
  • 25.Tibaijuka L, Odongo R, Welikhe E, Mukisa W, Kugonza L, Busingye I, et al. Factors influencing use of long-acting versus short-acting contraceptive methods among reproductive-age women in a resource-limited setting. BMC Women’s Health 2017;17(1):25. doi: 10.1186/s12905-017-0382-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.National Institute of Statistics of Rwanda (NISR), Ministry of Health (MOH), International I. Rwanda Demographic and Health Survey 2014–15. Rockville, Maryland, USA: Maryland, USA: NISR, MOH, and ICF International.: NISR, MOH, and ICF International., 2015.
  • 27.Huber-Krum S, Leigh Senderowicz L, Hackett K, Pearson E, Shah I, Siril H. Women’s Perspectives and Experiences Using Postpartum Intrauterine Device in Tanzania. In: America PAo, editor. 2019. [DOI] [PMC free article] [PubMed]
  • 28.Kumar S, Sethi R, Balasubramaniam S, Charurat E, Lalchandani K, Semba R, et al. Women’s experience with postpartum intrauterine contraceptive device use in India. 2014;11(1):32. doi: 10.1186/1742-4755-11-32 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Brunie A, Tolley EE, Ngabo F, Wesson J, Chen M. Getting to 70%: Barriers to modern contraceptive use for women in Rwanda. International Journal of Gynecology & Obstetrics. 2013;123:e11–e5. doi: 10.1016/j.ijgo.2013.07.005 [DOI] [PubMed] [Google Scholar]
  • 30.Cleland J, Ali M, Benova L, Daniele M. The promotion of intrauterine contraception in low- and middle-income countries: a narrative review. Contraception. 2017;95(6):519–28. Epub 2017/04/04. doi: 10.1016/j.contraception.2017.03.009 . [DOI] [PubMed] [Google Scholar]
  • 31.Khu NH, Vwalika B, Karita E, Kilembe W, Bayingana RA, Sitrin D, et al. Fertility goal-based counseling increases contraceptive implant and IUD use in HIV discordant couples in Rwanda and Zambia. Contraception. 2013;88(1):74–82. doi: 10.1016/j.contraception.2012.10.004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Ndayizigiye M, Fawzi MC, Lively CT, Ware NC. Understanding low uptake of contraceptives in resource-limited settings: a mixed-methods study in rural Burundi. BMC Health Serv Res. 2017;17(1):209. Epub 2017/03/17. doi: 10.1186/s12913-017-2144-0 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Robinson N, Moshabela M, Owusu-Ansah L, Kapungu C, Geller S. Barriers to Intrauterine Device Uptake in a Rural Setting in Ghana. Health Care Women Int. 2016;37(2):197–215. Epub 2014/08/26. doi: 10.1080/07399332.2014.946511 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Gonie A, Wudneh A, Nigatu D, Dendir Z. Determinants of family planning use among married women in bale eco-region, Southeast Ethiopia: a community based study. BMC Womens Health. 2018;18(1):50. Epub 2018/03/14. doi: 10.1186/s12905-018-0539-7 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Eliason S, Baiden F, Quansah-Asare G, Graham-Hayfron Y, Bonsu D, Phillips J, et al. Factors influencing the intention of women in rural Ghana to adopt postpartum family planning. Reproductive health. 2013;10:34. Epub 2013/07/23. doi: 10.1186/1742-4755-10-34 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Karita E, Nsanzimana S, Ndagije F, Wall KM, Mukamuyango J, Mugwaneza P, et al. Implementation and Operational Research: Evolution of Couples’ Voluntary Counseling and Testing for HIV in Rwanda: From Research to Public Health Practice. Journal of acquired immune deficiency syndromes (1999). 2016;73(3):e51–e8. Epub 2016/10/16. doi: 10.1097/QAI.0000000000001138 . [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Kehinde Sharafadeen Okunade

8 Aug 2022

PONE-D-22-16684A mixed-methods study of factors influencing postpartum intrauterine device uptake after family planning counseling among women in Kigali, RwandaPLOS ONE

Dear Dr. Wall,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Sep 22 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Kehinde Sharafadeen Okunade

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please include a complete copy of PLOS’ questionnaire on inclusivity in global research in your revised manuscript. Our policy for research in this area aims to improve transparency in the reporting of research performed outside of researchers’ own country or community. The policy applies to researchers who have travelled to a different country to conduct research, research with Indigenous populations or their lands, and research on cultural artefacts. The questionnaire can also be requested at the journal’s discretion for any other submissions, even if these conditions are not met.  Please find more information on the policy and a link to download a blank copy of the questionnaire here: https://journals.plos.org/plosone/s/best-practices-in-research-reporting. Please upload a completed version of your questionnaire as Supporting Information when you resubmit your manuscript.

3. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

4. Thank you for stating the following in the Acknowledgments Section of your manuscript:

“Financial support for this work was provided by the Bill & Melinda Gates Foundation, Emory University Research Council Grants, Emory Global Field Experience Program, National Institutes of Health and Emory AITRP Fogarty.”

We note that you have provided additional information within the Acknowledgements Section that is not currently declared in your Funding Statement. Please note that funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

“This work was supported by the Bill & Melinda Gates Foundation [OPP1160661]. Additional support came from the Emory University Research Council Grant [URCGA16872456], Emory Global Field Experience Award, the Emory Center for AIDS Research [P30 AI050409], the National Institutes of Health [NIAID R01 AI51231; NIAID R01 AI64060; NIAID R37 AI51231], and Emory AITRP Fogarty [5D43TW001042]. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

5. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability.

Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized.

Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access.

We will update your Data Availability statement to reflect the information you provide in your cover letter.

6. We note that you have stated that you will provide repository information for your data at acceptance. Should your manuscript be accepted for publication, we will hold it until you provide the relevant accession numbers or DOIs necessary to access your data. If you wish to make changes to your Data Availability statement, please describe these changes in your cover letter and we will update your Data Availability statement to reflect the information you provide.

7. Please include your tables as part of your main manuscript and remove the individual files. Please note that supplementary tables (should remain/ be uploaded) as separate "supporting information" files

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: No

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: General Comments:

Overall, the manuscript is well written. However, the meaning certain abbreviations should be clearly defined such L & D.

Specific Comments

Study design:

Although the choice of case-control study design was appropriate for the users and non-users of postpartum IUD, the sampling techniques and the ratio of users and non-users selected for study was not stated.

Results Section:

The tables referenced in the result section were not available for review in the submitted manuscript.

Reviewer #2: A mixed-methods study of factors influencing postpartum intrauterine device uptake after family planning counseling among women in Kigali, Rwanda

This study which aimed to ascertain factors that influenced postpartum intrauterine device uptake after family planning counseling among women in Kigali, Rwanda is quite relevant towards improving PPIUD uptake in developing countries which is vital for reduction of preventable maternal deaths.

Overall, the article has been fairly well written but there are sections that needs to be revised to improve the quality of the manuscript.

The quick point subsection should

Abstract

Abstract has not been written in accordance with journal specification for the subsections under the abstract. Please change discussion to conclusion

The result section stated that factors associated with PPIIUD (P-value <0.1) was what was used to make inferences. This should be reviewed and aligned with what has been written in the main text in which P-value P value <0.1 was considered for adjusted logistic regression analysis and not at the bivariate level

Conclusion is misleading due to the value of level of significance for which the null hypothesis will be rejected or accepted. (High chance of making type II error)

METHODS

Page 6, Lines 48-51: Paraphrase to:

Sites were selected because they were high volume facilities where CHWs and trained PPFP providers rendered PPFP services that included counseling in ANC, labor and delivery, postpartum (before discharge) and at 6-week infant vaccination visits

Page 9, lines 94-96:

Comment: The number of participants in this FGD seems too many to allow for a controlled and enabling focused discussion. Ideally it should not be more than 10 participants per FGD group. This is because large groups are difficult to control and they limit each person’s opportunity to make their observations or give their perspectives. This should be mentioned as a limitation to the study. How did the authors overcome this challenge?

Page 11, line 113

Comment: The reason for the compensation should be justified with a sentence.

Page 11, line 114-115

Comment: This was a case-control study; Therefore, the reports should be comparing the cases and the controls. Was the over 22% amongst women using PPPIUD currently or the non-users?

Page 13, lines 174-175

Comment: Rather than lump them as others which is not entirely true based on the responses. For example, not knowing or remembering a side effect doesn’t make it "others" and saying that there are no side effects doesn’t make it a type of side effect.

Page 14, line 198: Variables significant at P<0.01

Comment: This different from P<0.1 earlier presented in the methodology section. Please reconcile the two statements

Qualitative data:

This has not been reported appropriately: Please use the COREQ checklist and attach same as an appendix.

One important group which will answer the research question in the qualitative component of the study was conspicuously missing. This are the women who are eligible for PPIUD insertion. The omission of this group was a missed opportunity for a rich qualitative data from the perspective of the patients. This can be included in the limitation section

Tables

This was not attached in the manuscript

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Dr Godwin Akaba,MBBS,MSc,MPH,FWACS

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment

Submitted filename: Edit_PPIUD_Manuscript_09Jun22.doc

PLoS One. 2022 Nov 3;17(11):e0276193. doi: 10.1371/journal.pone.0276193.r002

Author response to Decision Letter 0


20 Sep 2022

Reviewer #1: General Comments:

Overall, the manuscript is well written. However, the meaning certain abbreviations should be clearly defined such L & D.

We have reviewed all abbreviations to make sure they are defined.

Specific Comments

Study design:

Although the choice of case-control study design was appropriate for the users and non-users of postpartum IUD, the sampling techniques and the ratio of users and non-users selected for study was not stated.

We now state that this study relied on a convenience sample with a target ratio of 1:1.

Results Section:

The tables referenced in the result section were not available for review in the submitted manuscript.

Apologies, I’m not sure why the tables were not viewable to the reviewers.

Reviewer #2: A mixed-methods study of factors influencing postpartum intrauterine device uptake after family planning counseling among women in Kigali, Rwanda

This study which aimed to ascertain factors that influenced postpartum intrauterine device uptake after family planning counseling among women in Kigali, Rwanda is quite relevant towards improving PPIUD uptake in developing countries which is vital for reduction of preventable maternal deaths.

We appreciate the reviewers positive and constructive comments.

Overall, the article has been fairly well written but there are sections that needs to be revised to improve the quality of the manuscript.

The quick point subsection should

Abstract

Abstract has not been written in accordance with journal specification for the subsections under the abstract. Please change discussion to conclusion

This edit has been made.

The result section stated that factors associated with PPIIUD (P-value <0.1) was what was used to make inferences. This should be reviewed and aligned with what has been written in the main text in which P-value P value <0.1 was considered for adjusted logistic regression analysis and not at the bivariate level.

We have ensured that the use of p<0.01 as the cut-off for statistical significance has been made consistently throughout the manuscript.

Conclusion is misleading due to the value of level of significance for which the null hypothesis will be rejected or accepted. (High chance of making type II error)

We now temper our findings in light of the potential for type II error.

METHODS

Page 6, Lines 48-51: Paraphrase to:

Sites were selected because they were high volume facilities where CHWs and trained PPFP providers rendered PPFP services that included counseling in ANC, labor and delivery, postpartum (before discharge) and at 6-week infant vaccination visits

This section has been paraphrased.

Page 9, lines 94-96:

Comment: The number of participants in this FGD seems too many to allow for a controlled and enabling focused discussion. Ideally it should not be more than 10 participants per FGD group. This is because large groups are difficult to control and they limit each person’s opportunity to make their observations or give their perspectives. This should be mentioned as a limitation to the study. How did the authors overcome this challenge?

This has been noted in the limitations section (though we also note that our FGS facilitators have been conducting FGDs for many years and are experienced at managing these discussions, we agree that these FGDs were larger than is customary).

Page 11, line 113

Comment: The reason for the compensation should be justified with a sentence.

We now note that the compensation level was that approved/set by the local IRB to compensate participants for their time without being coercive.

Page 11, line 114-115

Comment: This was a case-control study; Therefore, the reports should be comparing the cases and the controls. Was the over 22% amongst women using PPPIUD currently or the non-users?

The 22% is among the entire study population, and these data are described in table 1 stratified by PPIUD users and non-users. Apologies that the tables were not viewable by the reviewers.

Page 13, lines 174-175

Comment: Rather than lump them as others which is not entirely true based on the responses. For example, not knowing or remembering a side effect doesn’t make it "others" and saying that there are no side effects doesn’t make it a type of side effect.

We now clarify that ‘Other’ was an actual response option (not created post hoc), and choosing this option led to an open response option from which the responses were grouped as described in the text.

Page 14, line 198: Variables significant at P<0.01

Comment: This different from P<0.1 earlier presented in the methodology section. Please reconcile the two statements

This inconsistency in definition of the p-value cutoff has been corrected.

Qualitative data:

This has not been reported appropriately: Please use the COREQ checklist and attach same as an appendix.

This was a helpful suggestion – we have modified the manuscript to adhere to this checklist, which has been attached in the resubmission.

One important group which will answer the research question in the qualitative component of the study was conspicuously missing. This are the women who are eligible for PPIUD insertion. The omission of this group was a missed opportunity for a rich qualitative data from the perspective of the patients. This can be included in the limitation section.

We do not entirely understand this comment. All women studied were eligible for PPIUD insertion (there are very few contraindications to receiving the copper IUD at some point in the postpartum period). If more clarity on the comment can be provided so that the authors can understand the issue, we are happy to mention the issue in the limitations section.

Tables

This was not attached in the manuscript

Apologies, we are not sure why the tables were not viewable by the reviewers.

Attachment

Submitted filename: ResponseToReviewers_16Sept22.docx

Decision Letter 1

Kehinde Sharafadeen Okunade

2 Oct 2022

A mixed-methods study of factors influencing postpartum intrauterine device uptake after family planning counseling among women in Kigali, Rwanda

PONE-D-22-16684R1

Dear Dr. Wall,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Kehinde Sharafadeen Okunade

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

Kehinde Sharafadeen Okunade

12 Oct 2022

PONE-D-22-16684R1

A mixed-methods study of factors influencing postpartum intrauterine device uptake after family planning counseling among women in Kigali, Rwanda

Dear Dr. Wall:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Kehinde Sharafadeen Okunade

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Flowchart for case-control study participant recruitment.

    (DOCX)

    S1 Questionnaire. Inclusivity in global research questionnaire.

    (DOCX)

    Attachment

    Submitted filename: Edit_PPIUD_Manuscript_09Jun22.doc

    Attachment

    Submitted filename: ResponseToReviewers_16Sept22.docx

    Data Availability Statement

    All relevant data are available on Harvard Dataverse: https://doi.org/10.7910/DVN/GMXIMW.


    Articles from PLOS ONE are provided here courtesy of PLOS

    RESOURCES